Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA Is Hesitant About Using Observational Studies In Real-World Evidence Framework

Executive Summary

Agency plans guidance on whether observational studies can provide real-world evidence to support regulatory decisions about drug effectiveness; however, RWE framework includes critical questions about retrospective studies, and reflects agency concerns about transparency.


Advertisement

Related Content

Real-World Evidence: US FDA Framework Emphasizes Data Fitness And Study Quality
Real-World Data Could Get Boost From Trial Replication Project
Industry Need FDA 'Engaged' Before Investing In Observational Studies
Real-World Evidence: Efficacy Assessments Await FDA Clarity, Pilot Projects

Topics

Advertisement
UsernamePublicRestriction

Register

PS124381

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel